http://www.lsis.com/goto/r3/rss 2010-06-23T11:10:02+01:00 text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v3/%3B%97f%FA%15%7C%7D%7D The 1000 Genomes Project, an international public-private consortium to build the most detailed map of human genetic variation to date, announces the completion of three pilot projects and the deposition of the final resulting data in freely available public databases for use by the research community. In addition, work has begun on the full-scale effort to build a public database containing information from the genomes of 2,500 people from 27 populations around the world. Launched in 2008, the 1000 Genomes Project first conducted three pilot studies to test multiple strategies to produce a catalogue of genetic variants that are present in one percent or greater frequency in the different (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v3/%3B%97f%FB%1Cuys The completion of three pilot projects designed to determine how best to build an extremely detailed map of human genetic variation begins a new chapter in the international project called 1,000 Genomes, said the director of the Baylor College of Medicine Human Genome Sequencing Center, which is a major contributor to the effort. "Mapping all the shared normal variation in human populations is a critical step to interpreting medically actionable genetic changes," said Dr. Richard Gibbs, also a professor in the department of molecular and human genetics at BCM . The 1,000 Genomes project began in 2008 with the kickoff of three pilot programs. Completion of the pilots launches the full-scale (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%1Cuxz OCEANSIDE, Calif.-(BUSINESS WIRE)-International Stem Cell Corporation (OTCBB:ISCO), www.intlstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today that Charles J. Casamento was elected to the Board of Directors, on June 21, 2010. Mr. Casamento is a vital addition to our Board and brings to International Stem Cell Corporation expertise in areas that will help guide our company through growth, including corporate governance, business development, strategic planning, financing, mergers and acquisitions, product development, clinical trials and corporate and research and development collaboration activities Mr. Casamento is (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%1Cu%7C%7E WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the promotion to vice president of two executive directors Godfrey Amphlett, Ph.D., and Robert J. Lutz, Ph.D. who have played central roles in establishing ImmunoGen s highly successful product development capabilities. These functions complement the Company s strong research capabilities in ImmunoGen s advancement of its own novel anticancer compounds and the industry-leading target-to-commercial product expertise the Company provides to its partners. ImmunoGen has transitioned from being an organization with strong research to one (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%1Cu%7Es SCHAUMBURG, Ill.-(BUSINESS WIRE)-APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene -IV, which is marketed by Roche Laboratories, Inc. The addition of Ganciclovir for Injection further strengthens APP s broad anti-infective portfolio and market leadership position. APP will soon launch Ganciclovir for Injection and will package the product in single dose, 500 mg vials. APP's Ganciclovir for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%1Ctys CAMBRIDGE, Mass. and CARLSBAD, Calif.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): We and Isis congratulate Regulus on forming this important new alliance with sanofi-aventis. Regulus stands as the leader in the emerging field of microRNA therapeutics, and this new partnership reflects the high level of interest across the pharmaceutical industry for innovative medicines based on this new biology New Partnership Validates Alnylam and Isis Strategy for Shareholder Value Creation Regulus, Alnylam and Isis to Host Conference Call Webcast to Discuss Regulus-Sanofi-aventis Collaboration on June 22, 2010 at 8:30 a.m. ET (5:30 a.m. PT) Alnylam Pharmaceuticals, Inc. (Nasdaq: (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%1Ct%7Dr LOS ANGELES-(BUSINESS WIRE)-ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular s acquisition of Targepeutics worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2 (IL13Ra2). The agreement includes Targepeutics rights under an issued U.S. patent and under certain other issued or pending patents and applications. This licensing agreement further enhances our intellectual property estate of more than 40 patents and patent applications relating to active (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%1C%7F%7Bx Summary. Latent class analysis (LCA) and latent class regression (LCR) are widely used for modeling multivariate categorical outcomes in social science and biomedical studies. Standard analyses assume data of different respondents to be mutually independent, excluding application of the methods to familial and other designs in which participants are clustered. In this article, we consider multilevel latent class models, in which subpopulation mixing probabilities are treated as random effects that vary among clusters according to a common Dirichlet distribution. We apply the expectation-maximization (EM) algorithm for model fitting by maximum likelihood (ML). This approach works well, but (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%1Dtx%7E BACKGROUND: A new method (sLDL-EX "SEIKEN") is commercially available for the direct quantification of small dense LDL-cholesterol (sd-LDL) on automated chemistry analyzers, without manual sample pretreatment. We evaluated the performance of this direct assay to estimate the small dense LDL subclass phenotype ("non-A"), defined by polyacrylamide gel tube electrophoresis. METHODS: Fasting serum samples from 189 healthy subjects (age 18-75y, 96 females) were collected. The direct sd-LDL assay (from Randox Laboratories) was applied on a Roche Modular P analyzer. The Quantimetrix Lipoprint(TM) LDL System was used to define LDL subclass phenotypes (A and non-A). ROC curve analysis was performed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%1Dtvy BACKGROUND: Next-generation DNA sequencing (NGS) techniques have the potential to revolutionize molecular diagnostics; however, a thorough evaluation of these technologies is necessary to ensure their performance meets or exceeds that of current clinical sequencing methods. METHODS: We evaluated the NimbleGen Sequence Capture 385K Human Custom Arrays for enrichment of 22 genes. We sequenced each sample on both the Roche 454 Genome Sequencer FLX (GS-FLX) and the Illumina Genome Analyzer II (GAII) to compare platform performance. RESULTS: Although the sequence capture method allowed us to rapidly develop a large number of sequencing assays, we encountered difficulty enriching G+C-rich (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%13u%7F%7F BACKGROUND: We evaluated the analytical performance of 4 cystatin C assays (Siemens N Latex on BNII, Roche Gentian on Cobas c501, Genzyme on Cobas c501, and Tosoh ST AIA-PACK on Tosoh AIA-600II) according to guidelines published by the Clinical and Laboratory Standards Institute. METHODS: We evaluated total imprecision, limit of detection, and limit of quantification for each assay using patient serum pools and linearity/recovery using serial dilutions of a patient serum pool with cystatin C-free serum. We compared patients (n = 102) using the Siemens assay as a comparison method. RESULTS: All assays had limits of detection and quantification text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%13%7Ew%7F This study was purposed to establish a method for detecting miRNA expression by using fluorescent quantitative polymerase chain reaction (RQ-PCR), and to investigate the application value of this method in quantitative detection of miRNA. Total RNA was extracted from the peripheral blood or bone marrow of 82 patients with chronic lymphocytic leukemia (CLL) and 70 patients with acute leukemias (AL). Standard curves of U6 and miRNA were constructed from 10-fold serial dilutions of the cDNA, the quantitative detection was perfomed by using real-time quantitative PCR with SYBR Green by Roche Light Cycler. U6 RNA was used as the reference, the relative expression levels of miR-15a, miR-16-1, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%13%7F%7Fz Abstract Ecological opportunity - through entry into a new environment, the origin of a key innovation or extinction of antagonists - is widely thought to link ecological population dynamics to evolutionary diversification. The population-level processes arising from ecological opportunity are well documented under the concept of ecological release. However, there is little consensus as to how these processes promote phenotypic diversification, rapid speciation and adaptive radiation. We propose that ecological opportunity could promote adaptive radiation by generating specific changes to the selective regimes acting on natural populations, both by relaxing effective stabilizing selection (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FB%10%7Dwx SCHAUMBURG, Ill.-(BUSINESS WIRE)-APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene -IV, which is marketed by Roche Laboratories, Inc. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FB%10%7Dvr IRVING, Texas, June 22, 2010 (GLOBE NEWSWIRE) - Caris Life Sciences(TM), a leading biosciences company focused on driving precise and personalized healthcare, today announced that it has named Dominic P. Moorhead as President of European operations. This appointment and the expansion into Europe underline the growing demand for novel diagnostic, prognostic and theranostic testing services. European operations will play a pivotal role in the development and commercialization of the company's promising Carisome(TM) platform - a proprietary blood-based technology currently being developed for earlier, more accurate and less invasive testing for cancer and other complex diseases. In addition (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FB%10%7Dy%7D CARLSBAD, Calif.-(BUSINESS WIRE)-Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years. The alliance will initially focus on the therapeutic area of fibrosis. Regulus and sanofi-aventis will collaborate on (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v3/%3B%97f%FB%10%7D%7Bz 22.06.2010 - Evolva Holding SA announced that Dr. Jessica Mann will resign as Chief Medical Officer of Evolva as of 31 July 2010 to take up a Senior Development position as Head of Translational Medicine at Hoffman La Roche. Jessica Mann was clinical advisor of Evolva from February 2008 until October 2009 when she became Chief Medical Officer and she has been instrumental in the planning and implementation of Evolva s clinical activities during this period. As of 1 August 2010, Dr Mann will become a member of the Clinical Advisory Board of Evolva. At Roche, Dr Mann will lead the team in charge of early clinical development activities for the Metabolic DTA. Dr Alexandra Sorensen will (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v3/%3B%97f%FB%10%7Cyz ScienceDaily (June 21, 2010) The completion of three pilot projects designed to determine how best to build an extremely detailed map of human genetic variation begins a new chapter in the international project called 1,000 Genomes, said the director of the Baylor College of Medicine Human Genome Sequencing Center, which is a major contributor to the effort. See Also: Health & Medicine Human Biology Genes Personalized Medicine Diseases and Conditions Gene Therapy HIV and AIDS Reference Human Genome Project Human genome Genetics Antiviral drug Mapping all the shared normal variation in human populations is a critical step to interpreting medically actionable genetic changes, said Dr. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%11u%7D%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%11u%7C%7E SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it will webcast its Investor and Analyst Day at the Eventi hotel in New York City on June 24, 2010 from 4:15 p.m. to 5:45 p.m. Eastern time (1:15 p.m. to 2:45 p.m. Pacific). Overview of Muscle Disorders/Wasting and the Role for a SARM Therapeutic Presenters will include: John Higgins, President and Chief Executive Officer John Sharp, Vice President of Finance and Chief Financial Officer Robert McKay, Associate Director of Business Development Syed Kazmi, PhD, Vice President of Business Development Nezam Afdhal, MD, Chief of Hepatology, Beth Israel Deaconess in Boston œPresentation on (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%11tv%7D SAN DIEGO-(BUSINESS WIRE)-TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM.PK), a developer of transrenal molecular diagnostics, announced today that Skyline Diagnostics BV, a company which develops and commercializes diagnostic microarrays for oncology, has licensed its NPM1 technology to be included in one of its microarray products. Skyline Diagnostics plans to initially offer this product as a laboratory testing service in Europe and will eventually expand this testing service to markets outside of Europe. We are pleased that Skyline Diagnostics will be providing our NPM1 technology in an innovative microarray product as a laboratory testing service œWe are pleased that (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FB%11t%7Ex SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company (BMS) entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials. Given the recent progress of BMS wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and pace of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FB%11%7By%7E MedPage Today - Hypersensitivity problems with the experimental type II diabetes drug taspoglutide will delay its way to market, drug manufacturer Roche announced. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FB%11%7B%7B%7F PARIS, Jun 18, 2010 (BUSINESS WIRE) - Regulatory News: Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation. In the Phase III studies, the incidence of hypersensitivity reactions reported as related to taspoglutide is higher than expected for the study population, although it remains uncommon (i.e. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%11z%7C%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%16z%7E%7F Abstract This study was designed to investigate serum glucose, lipid, and lipoprotein in sheep naturally infected with Fasciola hepatica . Ten healthy sheep and 15 infected with F. hepatica were used in study. Serum concentrations of total protein (TP), albumin, glucose, cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoproteins (VLDL), and serum activities of AST, ALT, GGT, and LDH were measured using a Roche-Cobas Integra 800 auto-analyzer. At day 0 (prior to treatment) and on the 28th day (after treatment) the serum concentrations of TP, albumin, glucose, cholesterol, triglyceride, HDL, LDL, and VLDL values in sheep with F. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%17zy%7F Small RNA sequences were obtained from leaf extracts of wild Dactylis glomerata (cocksfoot grass) using deep sequencing (454 Life Sciences, Roche Diagnostics), and were screened against virus sequences in GenBank using a local BLASTn search program (BioEdit). Putative small interfering (si)RNAs complementary in sequence to Cereal yellow dwarf virus (CYDV, genus Luteovirus) genomes were identified. Primer sequences were made against the "high scoring" siRNA sequences and RT-PCR was used to amplify a 438bp CYDV fragment in total RNA extracts from D. glomerata leaves. Sequencing of the RT-PCR product confirmed the occurrence of a previously undescribed CYDV population with phylogenetic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FB%14%7E%7Fr PARIS-(BUSINESS WIRE)-Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN ADR: IPSEY), a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen s research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation. In the Phase III studies, the incidence of hypersensitivity reactions reported as related to taspoglutide is higher than expected for the study population, although it (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FB%15yv%7E The hypothenar eminence is of great surgical interest yet its complex anatomy is yet to be fully discovered. This review focuses on: the osteoligamentous floor and topography of the Guyon's canal and the carpal ulnar neurovascular space. The canal under the Pisohamate ligament must be individualized. It corresponds to the zone 2 of Shea and McClain where the deep branch of the ulnar nerve is particularly vulnerable. Usually described as a hole, it is a real canal that circumvents the hamulus; the hypothenar muscles are extremely variable. The short abductor of the little finger may be harvested for opposition transfer but its absence penalizes abduction of the little finger if an (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%1C%7Cv%7C Positron emission tomography/computed tomography (PET/CT) hybrid imaging can be used to gain insights into a synthetic siRNA delivery system targeted to the liver. Either siRNA or the delivery vehicle was labeled with (64)Cu via 1, 4, 7, 10- tetraazacyclododecane- 1, 4, 7, 10- tetraacetic acid (DOTA) chelation. This study confirmed that the siRNA delivery system was successfully targeted to the liver. Incorporation of the siRNA into the delivery system protected the siRNA from renal filtration long enough so that the siRNA could be delivered to the liver. PET/CT imaging was important for confirming biodistribution and for determining differences in the distribution of labeled siRNA, siRNA (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FC%12%7Bwy Bloomberg - Roche Holding AG, Johnson & Johnson and Biogen Idec Inc. are being urged by U.S. regulators to evaluate their hepatitis, cancer and anemia drugs for less- common ailments, after an incentive program to generate research into new medicines for neglected diseases failed. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FC%12%7Bz%7B PARIS-(BUSINESS WIRE)-Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN ADR: IPSEY), a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen s research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation. text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v3/%3B%97f%FC%12x%7Bx Preclinical findings recently published in Cancer Research, a journal of the American Association for Cancer Research, showed RG7204 (PLX4032) inhibited proliferation of tumor cell lines that expressed V600E-BRAF, a mutation found in several human cancers, including melanoma. The compound also showed partial or complete tumor regression and improved survival in a dose-dependent manner in preclinical efficacy models in rodents, without associated toxicity. BRAF mutations are found in about 8 percent of all solid tumors but in about 50 percent of melanomas. "Patients with advanced melanoma currently do not have a lot of options. There are some therapies, but the response rates are very low. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7E%7By CAMBRIDGE, Mass.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the œJohn et al.  patent (Application No. 10/384,463), which covers methods of inhibiting mutant genes with double-stranded RNAs from 19 to 30 nucleotides in length. Since mutations in genes underscore the genetics of inherited disease and cancer, as well as broader aspects of human disease associated with genetic variations, the John et al. patent covers broad therapeutic applications of RNAi therapeutics. a major scientific breakthrough that happens once (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7E%7Dx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f119e5/diabetes_care_devi) has announced the addition of the "Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC)" report to their offering. Diabetes Care Devices Market In Brazil, Russia, India & China (BRIC) This market research report analyzes the diabetes care devices market in Brazil, Russia, India, and China (BRIC) over the period 2009-2014. The report categorizes the overall market for diabetes care devices into the submarkets for insulin pumps, self-monitoring blood glucose systems, and continuous glucose monitoring systems. The diabetes care devices market in BRIC nations was (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7Dvx CAMBRIDGE, Mass.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 5th Annual Piper Jaffray Europe Conference on Wednesday, June 23, 2010 at 10:30 a.m. BST (5:30 a.m. ET) at the Andaz Liver Pool Street London Hotel. A live audio webcast of the presentation will be available on the œInvestors  section of the company s website, www.alnylam.com. A replay of the presentation will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7D%7Cz NEW YORK-(BUSINESS WIRE)-The Blackstone Group (NYSE: BX) today announced that Arthur J. Higgins, former Chairman of the Board of Management of Bayer HealthCare AG, has joined the firm s dedicated healthcare group, Blackstone Healthcare Partners. With the addition of Arthur Higgins we have further strengthened Blackstone Healthcare Partners. They offer a unique value to companies wishing to access focused industry expertise of this group of leading healthcare stars along with capital to fund growth. At Blackstone, Mr. Higgins will join health care veterans Lodewijk de Vink and Doug Rogers in providing industry knowledge and expertise to private equity transactions. Blackstone Healthcare (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7Cv%7D CAMBRIDGE, Mass.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has secured key intellectual property (IP) for RNAi applications in vaccine development by completing an exclusive option agreement with Mount Sinai School of Medicine in New York City and an exclusive license agreement with The University of Queensland in Brisbane, Australia. These new applications of RNAi technology define opportunities for the advancement of novel vaccines in many human diseases, including infectious disease and cancer. a major scientific breakthrough that happens once every decade or so œRNAi technology has become a game changer (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7Cv%7B MADISON, Wis.-(BUSINESS WIRE)-Roche NimbleGen (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) is pleased to announce that imaGenes GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for Comparative Genomic Hybridization (CGH). imaGenes is a solution provider for functional genomics and proteomics with a comprehensive portfolio of high-quality services for molecular life sciences. This is the third Roche NimbleGen certification for imaGenes to provide service for NimbleGen arrays. This follows the successful certification for ChIP-chip in December 2009 and DNA methylation analysis in February 2010, and makes imaGenes the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v3/%3B%97f%FC%12%7Cxs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8dd459/medicated_skin_car) has announced the addition of the "Medicated Skin Care in France" report to their offering. The beginning of de-regulation of OTC products came at the wrong moment. From July 2008, more than 200 OTC products, such as Activir by GlaxoSmithKline Sant Grand Public SAS in skin care, were available self-service, but only in chemists/pharmacies. For such self-service medicated skin care brands, consumers no longer had to ask the chemist/pharmacist to be able to buy the products. This change was said to have a positive impact on sales, because consumers could take time to choose (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%13%7Bxz CD147 is involved in many physiological functions, such as lymphocyte responsiveness, spermatogenesis, implantation, fertilization and neurological functions at early stages of development. Here we specifically review the role of CD147 in cancer. We focus on the following aspects: expression of CD147 in malignant versus normal tissues and its possible impact on prognosis, interaction of tumor cell-expressed CD147 with stroma cells and induction of matrix metalloproteinases, as well as the role of CD147 in tumor angiogenesis. The function of CD147 in supercomplexes with monocarboxylate transporters (MCT) and amino acid transporters such as CD98hc and large neutral amino acid transporter 1 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%13%7Dx%7B OBJECTIVES: R483 is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPARgamma) agonist with anti-diabetic properties and also a cytochrome P450 2C19 (CYP2C19) substrate. The aim of the clinical studies reported here was to investigate the influence of the CYP2C19 genotype on the pharmacokinetics (PK) of R483 in healthy subjects and in type 2 diabetes mellitus (T2DM) patients. METHODS: Data came from two clinical studies, one including 58 Japanese and Caucasian healthy subjects and another including 93 Asian T2DM patients. All subjects received multiple doses of R483, 20 mg once daily for the healthy subjects and 12 mg once daily for the T2DM patients. Blood samples (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%10%7B%7B%7F The purpose of this study was to evaluate the in vivo dose-response relation of chromosome aberration formation and distribution in a context of localised and fractionated radiotherapy. Cytogenetic analysis was applied to eight patients, all treated for the same tumour localisation; the same localisation was used to prevent the variability usually observed between patients treated with radiotherapy and to allow the corresponding roles of the size of irradiation field and of the dose rate to be studied. The yield of dicentrics, centric rings and fragments was measured in blood samples taken before treatment, during the course of radiotherapy and up to 6 months after. After the first (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%11xw%7B The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity that is in phase II and phase III clinical testing. Here, we report a preclinical characterization of the antitumor activity of RG7204 using established in vitro and in vivo models of malignant melanoma. RG7204 potently inhibited proliferation and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and ERK phosphorylation in a panel of tumor cell lines, including melanoma cell lines expressing BRAF(V600E) or other mutant BRAF proteins altered at codon 600. In contrast, RG7204 lacked activity in cell lines (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%11%7E%7F%7D Acoustic recordings from Palmyra Atoll, northern Line Islands, central Pacific, showed upsweep frequency modulated pulses reminiscent of those produced by beaked whales. These signals had higher frequencies, broader bandwidths, longer pulse durations and shorter inter-pulse intervals than previously described pulses of Blainville's, Cuvier's and Gervais' beaked whales [Zimmer et al. (2005). J. Acoust. Soc. Am. 117, 3919-3927; Johnson et al. (2006). J. Exp. Biol. 209, 5038-5050; Gillespie et al. (2009). J. Acoust. Soc. Am. 125, 3428-3433]. They were distinctly different temporally and spectrally from the unknown beaked whale at Cross Seamount, HI [McDonald et al. (2009). J. Acoust. Soc. Am. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%16%7B%7E%7C For some nursing students, the stress of preparing for and taking the NCLEX can lead to maladaptive behaviors such as poor test performance and inadequate preparation. A different approach to NCLEX preparation for at-risk seniors is described. A 3-credit course that combines cognitive behavioral techniques, metacognitive strategies, test-taking strategies, and simulated NCLEX experience with practice questions is presented. Students also develop an individualized plan of preparation from graduation until they take the NCLEX. |-| Nurse Educ. |-| Poorman SG, Mastorovich ML, Liberto TL, Gerwick M. |-| Authors' Affiliations: Professor (Dr Poorman), Associate Professor (Dr Gerwick), Department (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%14%7Bzs Cell Adh Migr. |-| Roche J, Drabkin H. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%14xyy Abstract Objective. The goal with this study was to evaluate the analytical performance of a new cystatin C immunoassay (Tina-quant(R) a Cystatin C, Roche Diagnostics GmbH). The evaluation was carried out at four centers according to a standardized protocol. Material and methods. The Tina-quant(R) a Cystatin C is a latex particle-enhanced immunoturbidimetric assay. Roche cobas(R) 6000, MODULAR ANALYTICS SWA and COBAS INTEGRA(R) instruments were included in the study. Method comparison studies were carried out against two turbidimetric methods (Dako Cystatin C, Gentian Cystatin C), and one nephelometric method (Siemens N-Latex Cystatin C). Results. Linearity was proven throughout (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v3/%3B%97f%FC%14%7F%7B%7E IL-2-inducible T cell kinase plays an essential role in T cell receptor signaling and is considered a drug target for the treatment of Th2-mediated inflammatory diseases. By applying high-throughput protein engineering and crystallization, we have determined the X-ray crystal structures of IL-2-inducible T cell kinase in complex with its selective inhibitor BMS-509744 and the broad-spectrum kinase inhibitors sunitinib and RO5191614. Sunitinib uniquely stabilizes IL-2-inducible T cell kinase in the helix C-in conformation by inducing side chain conformational changes in the ATP-binding site. This preference of sunitinib to bind to an active kinase conformation is reflective of its (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v3/%3B%97f%FD%1Ctys MADISON, Wis.-(BUSINESS WIRE)-Roche NimbleGen (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) is pleased to announce that imaGenes GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for Comparative Genomic Hybridization (CGH). imaGenes is a solution provider for functional genomics and proteomics with a comprehensive portfolio of high-quality services for molecular life sciences. This is the third Roche NimbleGen certification for imaGenes to provide service for NimbleGen arrays. This follows the successful certification for ChIP-chip in December 2009 and DNA methylation analysis in February 2010, and makes imaGenes the (…)